{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:35:37Z","timestamp":1782783337954,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03075-6","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T08:21:13Z","timestamp":1736929273000},"page":"1251-1264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia"],"prefix":"10.1007","volume":"42","author":[{"given":"Pengxiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalpa A.","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"1","key":"3075_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1744-859X-12-32","volume":"12","author":"JM Olivares","year":"2013","unstructured":"Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.","journal-title":"Ann Gen Psychiatry"},{"issue":"4","key":"3075_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"suppl 3","key":"3075_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"3075_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"key":"3075_CR5","doi-asserted-by":"crossref","unstructured":"McDonagh MS, Dana T, Selph S, et al. Treatments for schizophrenia in adults: A systematic review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017.","DOI":"10.23970\/AHRQEPCCER198"},{"issue":"6","key":"3075_CR6","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/schbul\/sbw043","volume":"42","author":"T Kishi","year":"2016","unstructured":"Kishi T, Matsunaga S, Iwata N. Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials. Schizophr Bull. 2016;42(6):1438\u201345.","journal-title":"Schizophr Bull"},{"key":"3075_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.psychres.2016.10.053","volume":"246","author":"T Kishi","year":"2016","unstructured":"Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trials. Psychiatry Res. 2016;246:750\u20135.","journal-title":"Psychiatry Res"},{"issue":"10","key":"3075_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","volume":"74","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957\u201365.","journal-title":"J Clin Psychiatry"},{"key":"3075_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.schres.2016.11.010","volume":"183","author":"G Ostuzzi","year":"2017","unstructured":"Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017;183:10\u201321.","journal-title":"Schizophr Res"},{"issue":"6","key":"3075_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603\u20139.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"3075_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"3075_CR12","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","volume":"44","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mehtala J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia\u2014a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381\u20137.","journal-title":"Schizophr Bull"},{"key":"3075_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380.","journal-title":"Schizophr Res"},{"issue":"3","key":"3075_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/schbul\/sbx090","volume":"44","author":"T Kishimoto","year":"2018","unstructured":"Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603\u201319.","journal-title":"Schizophr Bull"},{"issue":"9","key":"3075_CR15","first-page":"754","volume":"21","author":"SC Marcus","year":"2015","unstructured":"Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754\u201368.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"3075_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1176\/ps.2010.61.8.830","volume":"61","author":"E Khaykin","year":"2010","unstructured":"Khaykin E, Eaton WW, Ford DE, Anthony CB, Daumit GL. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv. 2010;61(8):830\u20134.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"3075_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13696998.2023.2189859","volume":"26","author":"P Li","year":"2023","unstructured":"Li P, Benson C, Geng Z, Seo S, Patel C, Doshi JA. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. J Med Econ. 2023;26(1):525\u201336.","journal-title":"J Med Econ"},{"issue":"5","key":"3075_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"3075_CR19","doi-asserted-by":"publisher","first-page":"sgac013","DOI":"10.1093\/schizbullopen\/sgac013","volume":"3","author":"P Takacs","year":"2022","unstructured":"Takacs P, Kunovszki P, Timtschenko V, et al. Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary: an update. Schizophr Bull Open. 2022;3(1):sgac013.","journal-title":"Schizophr Bull Open"},{"issue":"2","key":"3075_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","volume":"21","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295\u2013307.","journal-title":"World Psychiatry"},{"key":"3075_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/NDT.S395383","volume":"19","author":"R Milz","year":"2023","unstructured":"Milz R, Benson C, Knight K, et al. The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:531\u201345.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"21","key":"3075_CR22","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","volume":"367","author":"P Lichtenstein","year":"2012","unstructured":"Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006\u201314.","journal-title":"N Engl J Med"},{"issue":"17","key":"3075_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1001\/jama.2016.15380","volume":"316","author":"Z Chang","year":"2016","unstructured":"Chang Z, Lichtenstein P, Langstrom N, Larsson H, Fazel S. Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA. 2016;316(17):1798\u2013807.","journal-title":"JAMA"},{"issue":"19","key":"3075_CR24","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMsa020584","volume":"348","author":"WA Ray","year":"2003","unstructured":"Ray WA, Daugherty JR, Meador KG. Effect of a mental health \u201ccarve-out\u201d program on the continuity of antipsychotic therapy. N Engl J Med. 2003;348(19):1885\u201394.","journal-title":"N Engl J Med"},{"issue":"2","key":"3075_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334.","journal-title":"J Med Econ"},{"issue":"5","key":"3075_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4088\/JCP.14m09584","volume":"76","author":"L Alphs","year":"2015","unstructured":"Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554\u201361.","journal-title":"J Clin Psychiatry"},{"key":"3075_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2022.02.019","volume":"243","author":"L Alphs","year":"2022","unstructured":"Alphs L, Brown B, Turkoz I, Baker P, Fu DJ, Nuechterlein KH. The Disease Recovery Evaluation and Modification (DREaM) study: effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder. Schizophr Res. 2022;243:86\u201397.","journal-title":"Schizophr Res"},{"key":"3075_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/NDT.S3072","volume":"6","author":"JP Lindenmayer","year":"2010","unstructured":"Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat. 2010;6:261\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"3075_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.9758\/cpn.2016.14.4.323","volume":"14","author":"N Kar","year":"2016","unstructured":"Kar N, Barreto S, Chandavarkar R. Clozapine monitoring in clinical practice: beyond the mandatory requirement. Clin Psychopharmacol Neurosci. 2016;14(4):323\u20139.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"3075_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"3075_CR31","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1177\/0269881109104882","volume":"24","author":"MX Patel","year":"2010","unstructured":"Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists\u2019 use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5\u00a0years. J Psychopharmacol. 2010;24(10):1473\u201382.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"3075_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1176\/appi.ps.20230142","volume":"75","author":"JA Doshi","year":"2024","unstructured":"Doshi JA, Li P, Geng Z, Seo S, Patel C, Benson C. Out-of-pocket costs for long-acting injectable and oral antipsychotics among Medicare patients with schizophrenia. Psychiatr Serv. 2024;75(4):333\u201341.","journal-title":"Psychiatr Serv"},{"issue":"5","key":"3075_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469\u201381.","journal-title":"CNS Drugs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03075-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:54Z","timestamp":1738407234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03075-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3075"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03075-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pengxiang Li reported receiving personal fees from Cobbs Creek Healthcare and SKB Consulting Inc, all unrelated to the submitted work. Zhi Geng has nothing to disclose. Carmela Benson and Charmi Patel reported being employees of Janssen Scientific Affairs, LLC and stockholders of Johnson and Johnson. Jalpa Doshi reported receiving grants from Janssen Scientific Affairs, LLC during the conduct of the study; personal fees from AbbVie, Acadia, Janssen, Merck, Otsuka, and Takeda; and grants from Merck and Spark Therapeutics unrelated to the submitted work. No other authors had disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The University of Pennsylvania Institutional Review Board deemed this study exempt from review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}